Raschi E.; Fusaroli M.; La Placa M.; Ardizzoni A.; Zamagni C.; Poluzzi E.; De Ponti F., Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System, «AMERICAN JOURNAL OF CLINICAL DERMATOLOGY», 2022, 23, pp. 247 - 255 [articolo]
Lunghi C.; Trevisan C.; Fusaroli M.; Giunchi V.; Raschi E.; Sangiorgi E.; Domenicali M.; Volpato S.; De Ponti F.; Poluzzi E., Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People, «PHARMACEUTICALS», 2022, 15, Article number: 977, pp. 1 - 15 [articolo]Open Access
Raschi E.; Fusaroli M.; Massari F.; Mollica V.; Repaci A.; Ardizzoni A.; Poluzzi E.; Pagotto U.; Di Dalmazi G., The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System, «THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM», 2022, 107, pp. 3107 - 3114 [articolo]Open Access
Roberto G.; Girardi A.; Barone-Adesi F.; Pecere A.; Ientile V.; Bartolini C.; Da Cas R.; Spila-Alegiani S.; Ferrajolo C.; Francesconi P.; Trifiro G.; Poluzzi E.; Baccetti F.; Gini R., Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study, «FRONTIERS IN PHARMACOLOGY», 2022, 13, Article number: 871052, pp. 1 - 10 [articolo]Open Access
Galai E.; Scotti L.; Gilardetti M.; Ucciero A.; Ferrante D.; Poluzzi E.; Genazzani A.A.; Barone-Adesi F., Time-Trends of Drug-Drug Interactions among Elderly Outpatients in the Piedmont Region (Italy): A Population-Based Study, «INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH», 2022, 19, Article number: 7353, pp. 1 - 10 [articolo]Open Access
Lunghi, C; Fusaroli, M; Giunchi, V; Raschi, E; Zongo, A; Poluzzi, E, What Is the Safety Profile of Cannabis-Based Medications? Analysis of the Post-Marketing Signals from the FDA Adverse Event Reporting System, «DRUG SAFETY», 2022, 45, pp. 1242 - 1243 [abstract]
Baldin E.; Zenesini C.; Antonazzo I.C.; Bartolomei I.; Caniatti L.; Costa M.; Curti E.; Ferraro D.; Foschi M.; Granella F.; Guareschi A.; Immovilli P.; Lugaresi A.; Malagu S.; Mancinelli L.; Montepietra S.; Mussuto V.; Neri W.; Pasquinelli M.; Pellegrino L.; Pesci I.; Poluzzi E.; Pugliatti M.; Ravasio A.; Riise T.; Salvi F.; Santangelo M.; Sireci F.; Sola P.; Strumia S.; Tsantes E.; Vignatelli L.; Vitetta F.; Viti B.; D'Alessandro R., Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy, «NEUROEPIDEMIOLOGY», 2021, 55, pp. 224 - 231 [articolo]
Gatti M.; Ippoliti I.; Poluzzi E.; Antonazzo I.C.; Moro P.A.; Moretti U.; Menniti-Ippolito F.; Mazzanti G.; De Ponti F.; Raschi E., Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems, «CLINICAL NUTRITION», 2021, 40, pp. 1176 - 1185 [articolo]
Raschi, Emanuel; Fusaroli, Michele; Diemberger, Igor; Poluzzi, Elisabetta, Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”, «DRUG SAFETY», 2021, 44, pp. 505 - 506 [replica/breve intervento]
Gatti M.; Rinaldi M.; Ferraro G.; Toschi A.; Caroccia N.; Arbizzani F.; Raschi E.; Poluzzi E.; Pea F.; Viale P.; Giannella M., Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, «MYCOSES», 2021, 64, pp. 1317 - 1327 [articolo]Open Access
Gatti M.; Rinaldi M.; Ferraro G.; Toschi A.; Caroccia N.; Arbizzani F.; Raschi E.; Poluzzi E.; Pea F.; Viale P.; Giannella M., Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis, «MYCOSES», 2021, 64, pp. 1317 - 1327 [articolo]Open Access
Burato S.; Leonardi L.; Antonazzo I.C.; Raschi E.; Ajolfi C.; Baraghini M.; Chiarello A.; Delmonte V.; Di Castri L.; Donati M.; Fadda A.; Fedele D.; Ferretti A.; Gabrielli L.; Gobbi S.; Lughi S.; Mazzari M.; Pieraccini F.; Renzetti A.; Russi E.; Scanelli C.; Zanetti B.; Poluzzi E., Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region, «FRONTIERS IN PHARMACOLOGY», 2021, 11, Article number: 624888, pp. 624888 - 624895 [articolo]Open Access
Luxi N.; Giovanazzi A.; Capuano A.; Crisafulli S.; Cutroneo P.M.; Fantini M.P.; Ferrajolo C.; Moretti U.; Poluzzi E.; Raschi E.; Ravaldi C.; Reno C.; Tuccori M.; Vannacci A.; Zanoni G.; Trifiro G., COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety, «DRUG SAFETY», 2021, 44, pp. 1247 - 1269 [articolo]
Raschi E.; Fusaroli M.; Ardizzoni A.; Poluzzi E.; De Ponti F., Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, «BREAST CANCER RESEARCH AND TREATMENT», 2021, 186, pp. 219 - 227 [articolo]Open Access
Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E., Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 740707, pp. 1 - 11 [articolo]Open Access
